 This investigation is a sub-study of the 6-year multinational ESPRIT Evaluation of Subcutaneous Proleukin in a Randomized International Trial protocol. It will compare the effectiveness of the influenza FLUVAC and tetanus-pneumococcal TEPVAC vaccines in HIV-infected patients receiving interleukin-2 IL-2 plus anti-HIV drugs with those receiving only anti-HIV drugs. IL-2 is a protein naturally produced by immune cells called lymphocytes. Lymphocytes from patients with HIV do not produce IL-2 normally. The ESPRIT trial is evaluating whether HIV-infected patients treated with antiretroviral drugs plus IL-2 have fewer serious infections and improved survival than those receiving only anti-HIV drugs. 